🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Nuformix delighted as NXP004 testing exceeds the company’s expectations

Published 20/12/2022, 08:31
© Reuters.  Nuformix delighted as NXP004 testing exceeds the company’s expectations
NFXN
-

Proactive Investors - Nuformix PLC has updated investors on its NXP004 programme which is developing novel forms of AstraZeneca’s Olaparib (Lynparza®) cancer drug.

Lynparza generated US$2.7bn of sales in 2021 though has presented challenges historically in terms of "pill burden" and low olaprib bioavailability, the company noted, and, it has so far filed two patent applications covering novel forms of olaparib with the potential of protection out to 2041.

These novel forms of Olaparib have undergone tests which have shown enhanced dissolution of the drug, compared to dissolution, and the company today highlighted these positive results.

"I'm delighted with the results of the head-to-head dissolution studies, which exceeded my expectations and have demonstrated first-time that the lead NXP004 cocrystals offer significant scope for enhanced performance versus Lynparza®, for which biorelevant dissolution data is not in the public domain,” said executive director Dr Dan Gooding.

“The NXP004 cocrystals studied demonstrate some of the best dissolution performance I've seen from application of the technology - a step-change in dissolution performance, yet they appear to lack any of the common drawbacks that can hamper development of cocrystal-based products, which is surprising.

“These new data strongly support progression of the programme and we will now look to translate these enhancements into an in-vivo setting, which if successful will position the company well for commencing partnering discussions with multiple potential partners identified."

Nuformix told investors it will now look at the design of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of Olaparib, ahead of the commencement of talks with multiple potential commercialisation partners.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.